Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics’ Board of Directors as the Company advances its pipeline of novel TCR-based cell therapy and bispecific product candidates into the next phase of development.
“We are delighted to welcome Alise to the Board of Directors of Immatics. Alise has facilitated the approval and market launch of many impactful novel therapies and streamlined clinical development processes in many organizations,” said Peter Chambré, Chairman of Immatics’ Board of Directors. “Her exceptional clinical and strategic expertise will be of great value to the Board as Immatics seeks to move our TCR-based therapies for solid tumors closer to the market and to cancer patients with unmet medical need.”
“Immatics is at a dynamic stage of development, especially as the Company has demonstrated the maturation of deep and durable responses from its lead cell therapy candidate, ACTengine® IMA203, in advanced metastatic melanoma patients,” commented Alise Reicin, M.D. “I see real potential for Immatics’ two distinct TCR-based therapeutic modalities to address patients at various disease stages and with different solid tumor cancers. I look forward to working with the Board and supporting the Company as it strives to make a meaningful impact on the lives of cancer patients.”
Dr. Reicin brings extensive experience in early- and late-stage clinical development and a legacy of approved drugs in diverse therapeutic areas. Most recently, Dr. Reicin joined Tectonic Therapeutic, a company transforming the discovery of novel GPCR-targeted therapies, and, under her leadership, the company completed an $80 million Series A financing, moved its first asset into the clinic and entered the Nasdaq Global Market under the ticker symbol “TECX.” Before joining Tectonic Therapeutic, Dr. Reicin held leadership positions at several international pharmaceutical companies, including Celgene as President, Global Clinical Development, and EMD Serono as Senior Vice President, Global Head of Clinical Development. Dr. Reicin also held the position of Vice President, Project and Pipeline Leadership, Oncology Franchise, Merck Research Laboratories at Merck & Co. During her tenure, she led the initial development and filing activities that resulted in the first approvals of Keytruda® in the United States and European Union. Prior to Merck & Co., she was a full-time faculty member at Columbia Medical School as well as a physician and researcher at Columbia Presbyterian Hospital. Dr. Reicin received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University.
Dr. Reicin’s appointment to the Board of Directors continues through the Company’s Annual General Meeting in 2025.
- END -
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND or CTA filing for pre-clinical stage product candidates, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
| Media | |
| Trophic Communications | |
| Phone: +49 151 54041130 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Jordan Silverstein | |
| Head of Strategy | |
| Phone: +1 346 319-3325 | |
| InvestorRelations@immatics.com |
Attachment
